Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetrimide is a quaternary ammonium antiseptic and surfactant used primarily for topical disinfection and wound cleansing. It acts by disrupting the cell membranes of bacteria and other microorganisms, leading to bactericidal effects against Gram-positive bacteria and some Gram-negative organisms at higher concentrations. Cetrimide also exhibits variable antifungal activity and is effective against some viruses but is ineffective against bacterial spores[1][6][8]. It is commonly formulated as creams or solutions (typically 0.1–3%) for use on minor burns, wounds, abrasions, scalds, or in medicated shampoos for seborrheic dermatitis[2][3][5]. Cetrimide was first developed by ICI (Imperial Chemical Industries) and introduced under the brand name Cetavlon; it has also been widely marketed in combination with chlorhexidine as Savlon[4]. Its primary indications are wound care (including accident wounds), skin infection prevention/treatment, surgical preparation of skin, seborrheic dermatitis management (as shampoo), and dental applications[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cetrimide.